Reference
Kambhampati S, et al. Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series. Clinical Lymphoma, Myeloma & Leukemia 20: e118-e123, No. 3, Mar 2020. Available from: URL: http://doi.org/10.1016/j.clml.2019.12.014
Rights and permissions
About this article
Cite this article
Anti-CD19-CAR-transduced-T-cells/pembrolizumab. Reactions Weekly 1802, 37 (2020). https://doi.org/10.1007/s40278-020-77955-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-77955-7